PTYLTD
    • Free Reports
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic

By Topic

Megaport (ASX: MP1)

Why Megaport (ASX: MP1) Shares Just Skyrocketed More Than 35%?

May 15, 2026
Proactive Equities Team

Megaport (ASX: MP1) shares surged over 35% after the company secured AI infrastructure contracts worth A$254 million through Latitude.sh, strengthening its position in the booming AI compute and cloud connectivity market.

Pacific Edge (ASX: PEB)

Pacific Edge (ASX: PEB): Testing Critical Resistance, Breakout or Reversal Ahead?

May 19, 2026
Proactive Equities Team

Pacific Edge (ASX: PEB) tests critical resistance near 0.240 after surging on draft Medicare coverage, a 75% increase in reimbursement rates, and a NZ$25.4 million capital raise. Strong volume supports the rally, but RSI near 70 warns of potential pullback risk.

Stakk (ASX: SKK)

Stakk (ASX: SKK) Surges on Growth Momentum After Record Revenue Expansion

Jun 3, 2026
Proactive Equities Team

Stakk (ASX: SKK) has surged, reporting record $5.52 million in March quarter revenue and 186% growth, driven by its Stakk IQ embedded finance platform. Expanding across Australian and U.S. banks, healthcare, and regulated industries, it secured major contracts, lifting ARR toward A$26 million.

Hammer Metals (ASX: HMX)

Can Hammer Metals (ASX: HMX) Sustain Its Breakout Above Long-Term Resistance?

Jun 9, 2026
Proactive Equities Team

Hammer Metals, a junior explorer focused on copper, gold and lithium in Queensland and WA, broke above resistance on strong Kalman drilling and a trading halt tied to a potential control deal, though overbought technicals and exploration risk remain.

Alterity Therapeutics (ASX: ATH)

Is Alterity Therapeutics (ASX: ATH) Stabilising After Volatility at a Key Technical Level?

Jun 10, 2026
Proactive Equities Team

Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.

Cleanaway (ASX: CWY)

Can Cleanaway (ASX: CWY) Re Rate Higher as Margins Expand and Strategy 2030 Takes Hold?

Jun 14, 2026
Proactive Equities Team

Cleanaway (ASX: CWY) is rebuilding momentum through upgraded EBIT guidance, margin expansion, and a stronger strategic framework, with valuation support emerging as earnings and free cash flow accelerate.

...

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...567...37
Page 6 of 37